Cadence Capital Management’s BioTelemetry, Inc. BEAT Stock Holding History

Cadence Capital Management’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$330K	Sell	7,247 -24,251	-77%	-$1.01M	0.08%	225
2020 Q2	$1.42M	Buy	+31,498	New	+$1.41M	0.21%	150
2017 Q4	–	Sell	-72,964	Closed	-$2.41M	–	691
2017 Q3	$2.41M	Buy	72,964 +15,378	+27%	+$533K	0.15%	147
2017 Q2	$1.93M	Sell	57,586 -5,707	-9%	-$170K	0.13%	180
2017 Q1	$1.83M	Buy	63,293 +2,673	+4%	+$66.2K	0.13%	185
2016 Q4	$1.35M	Buy	60,620 +1,559	+3%	+$30.5K	0.09%	265
2016 Q3	$1.1M	Buy	59,061 +8,965	+18%	+$169K	0.08%	287
2016 Q2	$817K	Sell	50,096 -11,423	-19%	-$168K	0.06%	344
2016 Q1	$719K	Hold	61,519	–	–	0.05%	393
2015 Q4	$719K	Sell	61,519 -13,544	-18%	-$171K	0.05%	396
2015 Q3	$919K	Sell	75,063 -51,426	-41%	-$656K	0.06%	307
2015 Q2	$1.19M	Sell	126,489 -3,231	-2%	-$29.9K	0.07%	373
2015 Q1	$1.15M	Buy	+129,720	New	+$1.31M	0.07%	365

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Cadence Capital Management's BEAT Position: Q3 2020 in Review

Cadence Capital Management reduced its BioTelemetry, Inc. (BEAT) stake by 77% in Q3 2020, selling an estimated $1.01M and leaving 7,247 shares worth $330K. The position accounts for 0.08% of the portfolio, ranked #225.

Cadence Capital Management first reported a position in BEAT in Q1 2015 and has held it in 13 quarters since. The position peaked at $2.41M in Q3 2017. 209 funds tracked by Wall St. Rank hold BEAT as of Q3 2020.

Cadence Capital Management held 7,247 shares of BioTelemetry, Inc. worth $330K as of Q3 2020.
Cadence Capital Management sold 24,251 BioTelemetry, Inc. shares in Q3 2020, an estimated $1.01M.
BioTelemetry, Inc. made up 0.08% of Cadence Capital Management's portfolio in Q3 2020, its #225 holding.
Cadence Capital Management first reported a position in BioTelemetry, Inc. in Q1 2015 and has held it in 13 quarters since.
Cadence Capital Management's BioTelemetry, Inc. position peaked at $2.41M in Q3 2017.
209 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.